Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-12-08
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 530317, 530324, C07K 1458
Patent
active
058469320
ABSTRACT:
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
REFERENCES:
patent: 4496544 (1985-01-01), Needleman
patent: 4609725 (1986-09-01), Brady et al.
patent: 4673732 (1987-06-01), Kiso et al.
patent: 4716147 (1987-12-01), Tjoeng et al.
patent: 4757048 (1988-07-01), Lewicki et al.
patent: 4764504 (1988-08-01), Johnsn et al.
patent: 4804650 (1989-02-01), Lewicki et al.
patent: 4816443 (1989-03-01), Brady et al.
patent: 4861755 (1989-08-01), Breipohl et al.
patent: 4935492 (1990-06-01), Lewicki et al.
patent: 4952561 (1990-08-01), Scolnick et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: 5057495 (1991-10-01), Flynn et al.
patent: 5057603 (1991-10-01), Nutt et al.
patent: 5091366 (1992-02-01), Nutt et al.
patent: 5095004 (1992-03-01), Rakhit et al.
patent: 5106834 (1992-04-01), Bovy et al.
patent: 5159061 (1992-10-01), Fujino et al.
patent: 5204328 (1993-04-01), Nutt et al.
patent: 5212286 (1993-05-01), Lewicki et al.
patent: 5248764 (1993-09-01), Flanagan et al.
patent: 5418219 (1995-05-01), Ueda
patent: 5449662 (1995-09-01), Scarborough
patent: 5665704 (1997-09-01), Lowe et al.
Kangawa et al., Purification and Complete Amino Acid Sequence of Human Atrial Natriuretic Polypeptide ( -hANP0' Biochem Biophys Res. Comm., 118(1), pp. 131-139, 1984.
Rudinger, J. (1976). Peptide Hormones (ed. J.A. Parsons). University Park Press. Baltimore. pp. 1-7, Jun. 1976.
Bush et al., "Vasorelaxant Potencies and Receptor Binding Affinities of Atrial Natriuretic Hormone (ANH) Analogues" Fed. Proc. (Abstract Only) 45:657. 2919 (1986).
Cunningham et al., "Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor" EMBO Journal 13(11):2508-2515 (1994).
Dayhoff et al., "A Model of Evolutionary Change in Proteins" Atlas of Protein Sequence & Structure 5:89-99 (1972).
Engel et al., "A Single Residue Determines the Distinct Pharmacology of Rat and Human Natriuretic Peptide Receptor-C" Journal of Biological Chemistry 269(25):17005-17008 (1994).
Kangawa et al., "Purification and Complete Amino Acid Sequence of .alpha.-Human Atrial Natriuretic Polypeptide (.alpha.-hANP)" Biochem Biophys Res. Comm. 118(1):131-139 (1984).
Nutt et al., "Chemical Synthesis and Structure-Activity Relations for ANF Analogues" Endocrinology and Metabolism Clinics of North America 16(1):19-41 (1987).
Olins et al., "A Linear Analog of Atrial Natriuretic Peptide (ANP) Discriminates Guanylate Cyclase-coupled ANP Receptors from Non-coupled Receptors" The Journal of Biological Chemistry 263(22):10989-10993 (1988).
Rudinger, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence" Peptide Hormones, J.A. Parsons, Baltimore:University Park Press pp. 1-7 (1976).
Burnier John P.
Cunningham Brian C.
Lowe David G.
McDowell Robert S.
Oare David
Genentech Inc.
Gupta Anish
Kubinec Jeffrey S.
Tsang Cecilia J.
LandOfFree
Receptor specific atrial natriuretic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor specific atrial natriuretic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor specific atrial natriuretic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177252